Cellectar Trial for Breast Cancer

Cellectar has enrolled the first patient in a Phase 1b clinical trial for its CLR 125 Auger-emitting radioconjugate. This trial specifically targets refractory triple-negative breast cancer (TNBC), a particularly aggressive form of the disease. The study will evaluate the tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125. The goal is to determine the optimal dosage for future treatment protocols. This milestone represents a crucial step in developing new therapeutic options for patients with limited treatment alternatives.